Non-Exclusive Research License & Exclusive License To Develop was CRISPR Therapeutics AG’s largest revenue line in fiscal 2015, bringing in $132.60M of $162.90M (81%).
| Type Of Arrangement | FY 2015 |
|---|---|
| Non-Exclusive Research License & Exclusive License To Develop | $132.60M |
| Non-Exclusive Research License & Co-Exclusive License To Develop | $30.30M |
| Total | $162.90M |
CRISPR Therapeutics AG brought in $162.90M from its two revenue lines in fiscal 2015, the year ended October 26, 2015. Non-Exclusive Research License & Exclusive License To Develop was the largest at $132.60M (81.4%), ahead of Non-Exclusive Research License & Co-Exclusive License To Develop at $30.30M (18.6%).
CRISPR Therapeutics AG (CRSP) reports its revenue by type of arrangement. In fiscal 2015, Non-Exclusive Research License & Exclusive License To Develop was its largest revenue line, bringing in $132.60M (81.4% of the total), followed by Non-Exclusive Research License & Co-Exclusive License To Develop at $30.30M (18.6%).
Non-Exclusive Research License & Exclusive License To Develop was CRISPR Therapeutics AG's largest revenue line in fiscal 2015, bringing in $132.60M, or 81.4% of the $162.90M total across its two revenue lines.
Every figure comes from CRISPR Therapeutics AG's annual financial filings, as reported. Each line keeps the name CRISPR Therapeutics AG gives it, and years follow its fiscal calendar.
CRISPR Therapeutics AG's revenue by type of arrangement goes back to fiscal 2015, with figures through fiscal 2015. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.